Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by Stanford University
Information provided by (Responsible Party):
Heike E Daldrup-Link, Stanford University
ClinicalTrials.gov Identifier:
First received: February 24, 2012
Last updated: November 18, 2015
Last verified: November 2015

February 24, 2012
November 18, 2015
February 2012
October 2016   (final data collection date for primary outcome measure)
comparison of sensitivity, specificity and accuracy of WB-DW-MR scans to 18 F-FDG-PET scans. [ Time Frame: The outcome will be measured after image acquisition ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01542879 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.
A research study on the diagnosis of spread of disease for children who have been diagnosed with solid tumors using a new whole body MRI technique and a new MR contrast agent (ferumoxytol). Standard tests that are used to determine the extent and possible spread of a child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG) scanning. The purpose of this study is to determine if a newer imaging test referred to as whole body MR can detect the extent and spread of the disease as accurately or even better as the standard tests. The advantage of the new imaging test is that it is not associated with any radiation exposure. The results of whole body MR will be compared with that of the conventional, standard imaging studies for detecting distant metastases.

New developments in magnetic resonance (MR) imaging technology provide an alternative to radiographic staging techniques. Novel whole body (WB) diffusion weighted MR scans (WB-DW-MR) provide a very high tumor-to background contrast, similar to 18F-FDG PET scans. Therefore, this study was designed to compare the sensitivity of whole-body MR and 18F-FDG PET for detecting metastatic disease in children with malignant lymphomas and malignant sarcomas.

Pediatric patients with a newly diagnosed malignant lymphoma or malignant sarcoma, who are scheduled to undergo an 18F-FDG PET or PET/CT scan for tumor staging, will also undergo WB-DW-MR as an initial staging procedure prior to treatment. WB-DW-MR scans from head to toe will be obtained on a 3T MR system with an acquisition time of 30-60 minutes. Of note, the WB-DW-MR exam does not involve radiation exposure, anesthesia or any intravenous injection. Very young patients who would need an anesthesia or sedation for this study will be excluded in order to keep this initial research exam minimally invasive. Two experienced pediatric radiologists will determine the presence, location and size of primary tumors and metastases separately for the WB-DW-MR studies and 18F-FDG PET scans. The presence or absence of metastases will be confirmed by histopathology or clinical and imaging follow-up over at least one year as the standard of reference.

Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Device: WB-DW-MR scan
Experimental: WB-DW-MR scan
Intervention: Device: WB-DW-MR scan
Klenk C, Gawande R, Uslu L, Khurana A, Qiu D, Quon A, Donig J, Rosenberg J, Luna-Fineman S, Moseley M, Daldrup-Link HE. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Lancet Oncol. 2014 Mar;15(3):275-85. doi: 10.1016/S1470-2045(14)70021-X. Epub 2014 Feb 19.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2016
October 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age of less than 40 years
  • diagnosis of a malignant lymphoma or sarcoma
  • scheduled for or completed a PET or PET/CT tumor staging procedure.

Exclusion Criteria:

  • MR-incompatible metal implants
  • need of sedation
  • claustrophobia.
up to 40 Years
United States
PEDSVAR0017, SU-02242012-9149
Not Provided
Not Provided
Heike E Daldrup-Link, Stanford University
Heike E Daldrup-Link
Not Provided
Principal Investigator: Heike Daldrup-Link Stanford University
Stanford University
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP